Poseida Therapeutics (PSTX) Presents New Phase 1 Data at AAC

Poseida Therapeutics (PSTX) Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma

Poseida Therapeutics (PSTX) Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

San Diego , California , United States , American , Rajesh Belani , Bhagirathbhai Dholaria , Syed Rizvi , Poseida Therapeutics Inc , Clinical Development , American Association For Cancer Research , Nasdaq , Vanderbilt Ingram Cancer Center , Poseida Therapeutics , American Association , Cancer Research , Annual Meeting , Associate Professor , Chief Medical Officer , Subgroup Data , Optimizing Lymphodepletion , Solid Tumors Treated , Investigational Allogeneic , B Cell Maturation Antigen , Relapsed Refractory Multiple Myeloma , Patients Following Progression , Clinical Trials , Multiple Myeloma Patients , Achieve Adequate Lymphodepletion Necessary , Enable Allogeneic , Translational Medicine ,